Drugs / Zinc Supplement
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02126293 | Sep 2014 → Jan 2017 | chronic kidney disease, disorder of zinc metabolism | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT03112382 Comparator | Nov 2015 → May 2017 | type 2 diabetes mellitus | Cairo University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06075134 Background | Nov 2024 → Jun 2026 overdue | gingival disorder | Cairo University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zinc Supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06075134 ↗ |
| Route | Oral | “the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years” NCT02126293 ↗ |